AbbVie flashes eye-opening results for Rinvoq in alopecia areata
4th August 2025 Uncategorised 0While the JAK inhibitor market for alopecia areata has grown increasingly crowded in recent years, Rinvoq’s clinical performance in the disease could earn AbbVie a prominent seat at the table. After 24 weeks of treatment, Rinvoq at two doses—15 mg and 30 mg—helped 44.6% and 54.3% of adult alopecia patients achieve 80% or more scalp hair coverage, respectively, in a phase 3 trial.
More: AbbVie flashes eye-opening results for Rinvoq in alopecia areata
Source: fierce